anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients with low and selected intermediate risk prostate cancer are treated with Prostate LDR brachytherapy as monotherapy. 145 Gy is prescribed to the prostate. I-125 radioactive sources are used. Transperineal approach, rectal ultrasound guidance, inverse treatment planning, real time dose optimization is applied.
Patients receive tremelimumab IV over 60 minutes at weeks 1 and 5. Within 4-6 weeks later, patients undergo surgery or biopsy. After surgery or biopsy, patients receive tremelimumab IV Q4W for 3 doses, and then every Q12W in the absence of disease progression or unacceptable toxicity.
A mechanism is provided in a data processing system comprising a processor and a memory, the memory comprising instructions that are executed by the processor to specifically configure the processor to implement a data set generator. A statistics gathering engine executing within the data set generator calculates statistics and metrics across multiple data dimensions for a plurality of clients and a plurality of each client's data sources. The statistics gathering engine stores the statistics and metrics in a client-specific data map data structure for each client. An aggregated data map engine executing within the data set generator aggregates the statistics and metrics into an aggregated data map. The aggregated data map engine stores the aggregated data map in an aggregated data map data structure. The data set generator creates a client database construct. An insert engine executing within the data set generator populates the client database construct with new data based on the aggregated data map data structure.
Despite advances in prevention and treatment, barriers to adherence are common and HTN disparities remain pervasive. Populations that have been socially and economically disadvantaged have a greater prevalence of HTN, worse blood pressure control, and are at higher risk of developing CVD from HTN. Food insecurity (FI), the lack of consistent access to nutritionally adequate foods, is an important social need that affects 30 million people in the US, impacts adherence to treatment, and contributes to HTN disparities. Increasingly, health systems are investing in interventions to address FI as part of routine care, including lower-cost, low intensity (e.g. providing information about community resources) and higher-cost, high intensity (e.g. using community health workers (CHWs), delivery of medical tailored meals (MTM)) interventions
PURPOSE: Few longitudinal studies have investigated the mediating role of inflammation during childhood in associations between prenatal maternal stress and adolescent mental health. The objective of this study was to examine the associations between prenatal maternal stress, concentrations of immune markers at age 9, and symptoms of generalized anxiety disorder (GAD) and depression during adolescence.
METHODS: This study included 3723 mother-child pairs from the Avon Longitudinal Study of Parents and Children (ALSPAC). Prenatal maternal stress was examined using 55 items measured during pregnancy. Inflammation was assessed using serum concentrations of interleukin-6 (IL-6) and C-reactive protein (CRP) when children were 9 years old. GAD and depression were assessed when children were 16 and 18 years of age, respectively. Analyses comprised of structural equation models.
RESULTS: Prenatal maternal stress was associated with higher concentrations of IL-6 in childhood, and with greater symptoms of depression and GAD in adolescence. However, we did not observe associations between prenatal maternal stress and CRP; also, CRP and IL-6 were not associated with depression and GAD. There was no evidence that CRP and IL-6 mediated the associations between prenatal maternal stress and either GAD or depression.
CONCLUSIONS: Prenatal maternal stress is associated with IL-6 levels in childhood, and with GAD and depression during adolescence. Future studies should examine immune activity at multiple points during development in relation to mental health into adulthood to determine whether inflammation at different points during development could increase risk for mental health problems among children whose mothers experienced significant stressors during pregnancy.
Abstract for Magnesium Solution A magnesium oil that contains a plurality of salts and solvents that allows for a more complete skin and cellular absorption with little to no white salt residue left on skin. This oil does not require washing the skin after application. The solvents distilled water, 95% ethyl alcohol and glycerine provide the method of transporting through the skin membrane the much needed dissolved salts. To absorb the main salt magnesium chloride, cells often also rewire other elements comprising of potassium, boron, sodium and copper. These co-factors to absorption salts are included in the mixture and comprise of potassium chloride, sodium borate and cupric chloride. Date Recue/Date Received 2020-10-15
The invention relates to the field of cavitation treatment of liquid media and also of media in which the specific content of water or another liquid phase exceeds 30-35 % of the total mass. The method consists in placing containers of liquid media in a working fluid in a rectangular bath. The material of the liquid media-filled containers has a specific acoustic resistance equal to or approximating the specific acoustic resistance of the working fluid. A standing acoustic wave is created in the working fluid from all walls and the base of the bath, which are designed as flexible membranes having their own first harmonic resonance frequency. The length (a) and width (b) of the bath are chosen as multiples of one quarter of the length of the wave created in the working fluid by the side walls of the bath. The height (h) of the working fluid level is chosen as a multiple of one quarter of the length of the wave created by the base of the bath. The method enables the effective, simultaneous treatment of a plurality of different or identical compositions of liquid media, each of which is situated in its own container. Specifically, the method may be advantageously used in the preparation of individual cremes with a sub-micron size dispersion phase.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of PANHEMATIN use was evaluated in a compassionate use study. A total of 130 patients were treated with hemin for acute attacks, prophylaxis or both. Of those, 111 patients were administered hemin for treatment of 305 acute porphyria attacks and to 40 patients for prophylaxis. The majority (92%) of patients were Caucasian. Most (72%) were female; all adult patients had a mean age ± SD of 40.3 ± 12.3 years. Proportionally more females (15 out of 19) received prophylaxis or a combination of acute treatment and prophylaxis (19 out of 21). For the treatment of acute attacks, patients received 2 to 4 mg/kg/day PANHEMATIN intravenously for 1 to 9 doses. For prophylaxis patients, the most common doses were weekly or biweekly infusions. 

Table 1 summarizes adverse reactions occurring in >1% of patients treated with PANHEMATIN, categorized by body system and order of decreasing frequency.
Patients will receive ferumoxytol-enhanced renal magnetic resonance imaging before renal angiography. Ferumoxytol (510 mg/17mL; Chia Tai Tianqing Pharmaceutical Group Co Ltd, Nanjing, China) will be diluted at 1:4 (v/v) and intravenously infused into the antecubital vein at a dose of 3 mg/kg with an infusion speed of 0.07 mL/s.
The present invention relates to a 'Kangchining' cream which is an external paste for curing oral diseases. The external paste of the present invention has the functions of inhibiting bacteria, relieving inflammation, alleviating pain and arresting hemorrhage, and is suitable for treating and preventing gingivitis and periodontitis. When the present invention is prepared, moisturizing agents, binding agents, calcium carbonate and water are used as substrates, clove oil and borax are used as pharmacodynamic main ingredients, and flavouring agents and foaming agents are used as auxiliary ingredients. The external paste is prepared by the procedures of gelling, mixing, grinding, degassing, etc. The external paste of the present invention has the characteristics of high medical effect, no side effect and convenient application. After 14 days of medication, the effective rate reaches 100%, and the effective rate reaches 84.4%.
ISSUE ADDRESSED: This study explored trends in public support for obesity prevention policies in Western Australia (WA).
METHODS: A series of cross-sectional surveys of a representative sample of WA adults aged 25-49 years (N = 11 534) were undertaken between 2012 and 2020 as part of an evaluation of the LiveLighter® mass media campaign, a component of a statewide healthy lifestyle education and promotion programme. Computer-assisted telephone interviews were used to gauge support for a range of obesity prevention initiatives that could be implemented by government.
RESULTS: A majority of respondents supported a range of obesity prevention policies, including taxes on sugary drinks, urban planning regulations, food labelling and packaging regulations, restrictions on advertising and sponsorship, bans on the sale and marketing of unhealthy food and drink in retail environments and support for education and campaigns. Obesity prevention policies were highly supported by women, people with a healthy weight, and those who had completed secondary school. Support for regulation was high compared to other studies. Notably, there were significant increases in support between baseline and 2020 for 'taxing soft drinks and using the money to reduce the cost of healthy food' (72% cf. 80%) and 'restricting junk food promotions/advertisements on public transport' (73% cf. 83%).
CONCLUSIONS: There is substantial public support for regulatory action on obesity prevention in WA, providing strong rationale for government interventions to improve nutrition and reduce obesity. The LiveLighter® programme may have contributed to increases in support for obesity prevention policies in WA. SO WHAT?: There is potential to implement robust obesity prevention policies in WA.
PURPOSE:To impart a host with the productivity of a physiologically active substance, by treating a chromosome DNA of microorganism capable of producing a specific useful physiologically active substance with a restriction enzyme, thereby producing a plasmid containing DNA fragments, etc. CONSTITUTION:A chromosome DNA of a microorganism capable of producing a specific useful physiologically active substance when cultured in a medium containing a specific inducing substrate is treated with a restriction enzyme. The objective plasmid contains the DNA fragments produced by the above enzymatic treatment and is able to impart a host with the capability to produce the useful physiologically active substance even by culturing in a medium free of the above inducing substrate. A microbial strain transformed by the plasmid is cultured in a medium free of the inducing substrate, and the objective useful physiologically active substance is collected from the culture product. The inducing substrate is e.g. N-acylneuraminic acid and the useful physiologically active substance is e.g. N-acylneuraminic acid aldolase.
1. An intranasal pharmaceutical formulation for the treatment of male erectile dysfunction or female sexual disorders which comprises sildenafil mesylate, together with a pharmaceutically acceptable diluent or carrier in a form adapted for intranasal administration. 2. An intranasal formulation as claimed in Claim 1 in the form of an aqueous solution or powder formulation. 3. An intranasal formulation as claimed in Claim 1 comprising sildenafil mesylate in 5% weight/volume aqueous glycerine. 4. An intranasal formulation as claimed in Claim 1 comprising sildenafil mesylate and caffeine in a buffered aqueous solution. 5. An intranasal formulation as claimed in Claim 4 comprising sildenafil mesylate 100 mg/ml and caffeine 15mg/ml, in an aqueous solution buffered to pH 4.2. 6. An intranasal powder formulation as claimed in Claim 1 comprising sildenafil mesylate having a particle size of from 5 to 40 micrometres optionally with a pharmaceutically acceptable carrier. 7. An intranasal pharmaceutical presentation comprising sildenafil mesylate together with a pharmaceutically acceptable diluent or carrier as claimed in any one of Claims 1 to 6 in an intranasal delivery system or device. 8. A method of treating male erectile dysfunction or female sexual disorders which comprises intranasal administration of an effective amount of sildenafil mesylate. 9. Sildenafil mesylate. 10. Sildenafil mesylate, crystalline mono- or dihydrate.
The present invention relates to a soluble micro-needle and a micro-needle patch including the micro-needle. When skin is punched by using the micro-needle and the micro-needle is inserted through the punched skin, the micro-needle is dissolved, and a target material in the micro-needle is administrated into the skin. When the micro-needle according to the present invention is used, suitable mechanical strength, viscosity, and hardness are ensured. Thus, the micro-needle according to the present invention can be easily inserted in skin without being deformed by being bent or broken, and skin can be effectively punched. Moreover, the micro-needle according to the present invention is dissolved through the punched skin, and a target material shows an excellent skin transmittance rate. Compression using strong power is not needed. Irrespective of the part where a target material is contained in the micro-needle according to the present invention, the target material can be effectively transferred into skin.
PURPOSE: To inexpensively obtain a deriv. useful as an intermediate for anthracycline-based anticancer antibiotics having an antitumor effect by bringing a special compd. into substitution reaction to halobenzoylate the compd., then reacting the compd. with a metal halide, etc.  
     CONSTITUTION: The objective compd. of formula V [B 1 , B 2  are H, a hydroxy protecting group, etc.; R 1 , R 2  form alkylene, etc., together with the 5 - the position carbon on sugar skeleton; the compd. of formula VI (B 1 , B 2  are H, acetyl; A is H, methyl, etc.) is precluded] is obtd. by reacting Na-benzoate with the compd. of formula I (A is H, a 1 to 5C alkyl, etc.; B 2  is a hydroxyl acid dissociation group; Ph is phenyl; Hal is F, Cl, etc.) to obtain the compd. of formula II (Bz is benzoyl), halobenzoylating this compd. to form the compd. of formula III, reacting the compd. of the formula III with a metal halide in an amine solvent to obtain the compd. of formula IV and subjecting this compd. to hydrogenation in the presence of a metal contact reducing agent and further subjecting the compd. to debenzoylation. For example, methyl-2,6-dideoxy-2- fluoro-α-L-talopyranomide. 
     COPYRIGHT: (C)1992,JPO
BACKGROUND: Harm reduction (HR) is a critical response to the pronounced toxicity deaths being experienced in Canada. HR providers report many benefits of their jobs, but also encounter chronic stress from structural inequities and exposure to trauma and death. This research study sought to quantify the emotional toll the toxicity emergency placed on HR providers (Cycle One; 2019). Study objectives were later expanded to determine the impact of the ongoing toxicity as well as the pandemic's impact on well-being (Cycle Two; 2021).
METHODS: Standardized measures of job satisfaction, burnout, secondary traumatic stress, and vulnerability to grief were used in an online national survey. Open-ended questions addressed resources and supports. HR partners across Canada validated the findings and contributed to alternative interpretations and implications.
RESULTS: 651 respondents in Cycle One and 1,360 in Cycle Two reported moderately high levels of job satisfaction; they reported finding great meaning in their work. Yet, mean levels of burnout and secondary traumatic stress were moderate, with the latter significantly increasing in Cycle Two. Reported vulnerability to grief was moderate but increased significantly during COVID. When available, supports lacked the quality necessary to respond to the complexities of HR workers' experiences, or an insufficient number of sessions were covered through benefits. Respondents shared that their professional quality of life was affected more by policy failures and gaps in the healthcare system than it was by the demands of their jobs.
CONCLUSION: Both the benefits and the strain of providing harm reduction services cannot be underestimated. For HR providers, these impacts are compounded by the drug toxicity emergency, making the service gaps experienced by them all the more critical to address. Implications highlight the need for integration of HR into the healthcare system, sustainable and reliable funding, sufficient counselling supports, and equitable staffing models. Support for this essential workforce is critical to ensuring the well-being of themselves, the individuals they serve, and the health of the broader healthcare system.
<P>PROBLEM TO BE SOLVED: To provide a laxative having mild purging activity and providing little diarrheal symptom, and to provide a food containing the laxative.  <P>SOLUTION: The laxative contains genkwanin 5-O-β-primeveroside as an active ingredient. In one embodiment, the laxative contains iriflophenone 2-O-α-rhamnoside as an active ingredient. In another embodiment, the laxative contains an essence of leaves of Aquilaria sinensis which contains the genkwanin 5-O-β-primeveroside as an active ingredient. Also, the laxative contains the leaves of the Aquilaria sinensis which is an origin of the leaves of the Aquilaria sinensis. The food contains the laxative. The food can be a supplement.  <P>COPYRIGHT: (C)2007,JPO&INPIT
PROBLEM TO BE SOLVED: To provide a compound used for treating cancer patients.SOLUTION: There are provided a 9,10-α,α-OH-taxane compound and a process for producing the same. Novel and useful compounds used for the treatment of cancers are also provided. Intermediates used for forming compounds useful for the treatment of cancers are also provided. A method used for producing taxane analogs used for the treatment of cancers and derivatives thereof are further provided. Formulations to treat cancers in patients are proposed, and the formulations contain taxane at a selected concentration and a pharmaceutically acceptable carrier therefor. For example, the compound is represented by formula (I).
Neptune Krill Oil(TM)softgels (1g QD). Each softgel of Neptune Krill Oil will provide approximately 150 mg EPA and 100 mg DHA.
The invention belongs to the field of polymer chemistry, relates to a pharmaceutical preparation, and particularly relates to a hyaluronic acid-isoliquiritigenin conjugate, a dissolving type microneedle patch, a preparation method and application. (1) Synthesizing an isoliquiritigenin-loaded hyaluronic acid macromolecular long chain. (2) The hyaluronic acid-isoliquiritigenin conjugate is self-assembled and wrapped in water solution to form nanoparticles. (3) The conjugate has certain antitumor activity, and can inhibit proliferation and migration of mouse melanoma B16 cells. (4) The invention uses hyaluronic acid-isoliquiritigenin nano-particles with pharmacological activity as a matrix material of a dissolving type microneedle body. The microneedle prepared from hyaluronic acid-isoliquiritigenin can be loaded with other drugs with anti-tumor effects, can increase the drug content of tumor parts, reduce the side effects of the drugs on normal tissues, can play a role in multiple anti-tumor effects, and remarkably improve the treatment effect of the drugs on skin melanoma.
This is a Phase 1, randomized, 2 way crossover, open label study of the effect of PF-04965842 on metformin (a probe for MATE1/2K activity) PK in healthy adult participants. The effect of PF-04965842 on N1-methylnicotinamide (NMN; an endogenous biomarker for MATE1/2K) PK and its correlation to the effect on metformin PK will also be assessed. Participants will be randomized to 1 of 2 treatment sequences as described below. A total of 12 healthy male and/or female participants will be enrolled in the study so that 6 participants will be enrolled in each treatment sequence. Each treatment sequence will consist of 2 periods. Participants who discontinue from the study may be replaced at the sponsor's discretion. The replacement participant will receive the same treatment sequence as the participant who discontinued.

Participants will be screened within 28 days of the first dose of investigational product. Participants will report to the clinical research unit (CRU) the day prior to Day 1 (ie Day -1) dosing in Period 1 for both treatment sequences. In both sequences, participants will remain in the CRU for a total of 8 days and 7 nights (including Period 1 and Period 2). There will be a minimum 4 day washout period between metformin dosing events. NMN and metformin PK will be assessed in plasma and urine over 24 and 48 hours, respectively.
PCT No. PCT/US93/02619 Sec. 371 Date Dec. 5, 1994 Sec. 102(e) Date Dec. 5, 1994 PCT Filed Mar. 22, 1993 PCT Pub. No. WO93/18793 PCT Pub. Date Sep. 30, 1993This invention discloses new targeted conjugates for the delivery of a compound, and particularly, a steroid, to vascular endothelial cells. The conjugates comprise two components, preferably linked by a selectively-hydrolyzable bond, such as an acid-labile bond or enzyme-sensitive bond. The first component, a polyanionic polymer, and preferably, a polysulphated polymer such as a heparin-derivative, specifically directs the conjugate to vascular endothelial cells. The second component is a selected agent, such as a steroid, which exerts a specific effect on the target cell following its release. In particular, the present invention provides novel conjugated angiogenesis inhibitors, for use in the treatment of pathogenic conditions including cancer, arthritis, and diabetic blindness. An inhibitor comprising a heparin derivative and the anti-angiogenic steroid, cortisol, is herein shown to be markedly acid-labile, to suppress DNA synthesis and cell migration in human umbilical vein endothelial cells, to retard or abolish (depending pending on the route of injection) the vascularization of sponges in vivo and to retard lung tumor growth in mice by 65%. No adverse effects of the conjugate were detected, and equivalent treatments with a mixture of heparin plus cortisol were significantly less effective in all cases.